Black Box Appears Unlikely For Singulair Ahead Of US FDA Panel Review Of Pediatric Safety
Executive Summary
US FDA seeking recommendations on further labeling and communication strategies for Merck's Singulair, which has long carried a risk of neuropsychiatric events, from the agency's Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee.